CompletedNot Applicable

Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm)

Spain350 participantsStarted 2019-02-17

Plain-language summary

This prospective registry is intended to evaluate the safety and efficacy of the Optimax® stent.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with age ≥ 18 years old. * Patients with de novo coronary lesion treated with Optimax® stent, reference diameter = 3.0 mm and length ≤ 20 mm. * Informed consent signed. Exclusion Criteria: * Refusal of the patient to participate at the study. * Treatment of other injuries that do not meet the conditions (3x20).

What they're measuring

Safety. The number of composite events of cardiac.

Timeframe: 6 and 12 month

Efficacy: Incidence of clinically driven target lesion revascularization (TLR).

Timeframe: 6 and 12 month

Trial details

NCT IDNCT03737565

SponsorFundación EPIC

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-02

View on ClinicalTrials.gov More Coronary Artery Disease trials